Publication date: Available online 9 January 2019
Source: The Journal of Emergency Medicine
Author(s): Billy Sin, Iain Jeffrey, Zachary Halpern, Adebanke Adebayo, Tom Wing, Amy S. Lee, Josel Ruiz, Kevin Persaud, Lilia Davenport, Sylvie de Souza, Mollie Williams
Abstract
Background
Patients in the United States frequently seek medical attention in the emergency department (ED) to address their pain. The intranasal (i.n.) route provides a safe, effective, and painless alternative method of drug administration. Sufentanil is an inexpensive synthetic opioid with a high therapeutic index and rapid onset of action, making it an attractive agent for management of acute pain in the ED.
Objective
The objective of our study was to evaluate the safety and efficacy of i.n. sufentanil as the primary analgesic for acute pain in the ED.
Methods
This was a single-center, prospective, randomized, double-blind, double-dummy, controlled trial that evaluated the use of i.n. sufentanil 0.7 μg/kg via mucosal atomizer device vs. intravenous morphine 0.1 mg/kg in adult patients who presented to the ED with acute pain. The primary outcome was patient's pain score at 10 min after administration of intervention. Secondary outcomes were adverse events, the need for rescue analgesia, and patient satisfaction after treatment.
Results
Thirty patients were enrolled in each group. There was no significant difference in pain scores at 10 min after administration of intervention (sufentanil: 2.0, interquartile range = 2.0–3.3 vs. morphine: 3.0, interquartile range = 2.0–5.3, p = 0.198). No serious adverse events were reported. Rescue analgesia was not requested in either group. No significant difference in median satisfaction scores was found.
Conclusion
The use of i.n. sufentanil at 0.7 μg/kg/dose resulted in rapid and safe analgesia with comparable efficacy to i.v. morphine for up to 30 min in patients who presented with acute pain in the ED.
from Emergency Medicine via xlomafota13 on Inoreader http://bit.ly/2VI241R
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου